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ABSTRACT 
 
Several aspects of sleep behaviour such as timing, duration and quality have been 
demonstrated to be heritable. To identify common variants that influence sleep traits 
in the population, we conducted a genome-wide association study of 6 sleep 
phenotypes assessed by questionnaire in a sample of 2,323 individuals from the 
Australian Twin Registry. Genotyping was performed on the Illumina 317K, 370K 
and 610K arrays and the SNPs in common between platforms were used to impute 
non-genotyped SNPs. We tested for association with more than 2,000,000 common 
polymorphisms across the genome. While no SNPs reached the genome-wide 
significance threshold, we identified a number of associations in plausible candidate 
genes. Most notably, a group of SNPs in the 3rd intron of the CACNA1C gene ranked 
as most significant in the analysis of sleep latency (p = 1.3 x 10-6). We attempted to 
replicate this association in an independent sample from the Chronogen Consortium 
(n = 2,034), but found no evidence of association (p = 0.73). We have identified 
several other suggestive associations that await replication in an independent sample. 
We did not replicate the results from previous genome-wide analyses of self-reported 
sleep phenotypes after correction for multiple testing. 
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Introduction 
Despite the fact that insomnia is the most common sleep disorder, little is known 
about the contribution of genetics to its etiology and pathophysiology.  Between 6 and 
10% of individuals experience insomnia that is chronic in nature, while another 25% 
report occasional difficulties with sleep 1. Insomnia is associated with a number of 
negative sequelae including fatigue, irritability and impaired concentration and 
memory.  Longitudinal studies have also repeatedly shown that insomnia is a risk 
factor for the development of new-onset mood, anxiety, and substance-use disorders 2. 
Given the prevalence of insomnia and its associated public health impact, advances in 
our understanding of the genetic underpinnings of the disorder could lead to 
prevention and treatment efforts that would benefit a substantial proportion of the 
population.   
 One of the difficulties in studying the genetics of insomnia is the lack of 
standardized phenotypes.  Human genetic studies have largely relied on self-report, 
including one or more questions related to sleep patterns of characteristics such as 
sleep latency, time spent awake during the night, or total sleep time.  A number of 
studies have demonstrated that part of their variability can be attributed to genetic 
factors.  Several groups have conducted classical twin studies, comparing 
concordance in MZ and DZ twins 3-6. With only a few exceptions, heritability 
estimates were consistently in the range of .25 to .45, regardless of the exact insomnia 
question or phenotype used, indicating that self-reported insomnia has moderate 
genetic influences.  Studies where individuals were asked to report on sleep patterns 
of family members also provide support for genetic influences 7-11. The search for 
specific genes that are associated with sleep patterns and insomnia is in its infancy, 
but initial studies point in a number of directions.  Candidate gene studies in animals 
and humans have found associations between insomnia phenotypes and circadian 
clock genes such as BMAL/Mop3 12, PER3 13, and CLOCK 14. However, many of 
these analyses had small sample sizes by comparison to those used in genome-wide 
association studies. A recent analysis of common variants located in genes known to 
be involved in the circadian clock revealed an association between TIMELESS and 
symptoms of depression and sleep disturbance15. 
 A number of genome wide association studies (GWAS) have been conducted 
on sleep phenotypes in humans. Gottlieb and colleagues studied a subset (n=749) of 
the Framingham Heart Study Offspring Cohort using both linkage and association 
analysis 16.  Their survey included assessments of self-report sleep onset time (SSOT) 
and sleep duration, phenotypes that might have some relevance for insomnia.  
Linkage analysis failed to find any peaks with LOD>3, but five peaks with LOD>2 
were found, including a linkage between usual bedtime and CSNK2A2, a gene known 
to be a component of the circadian molecular clock.  In population-based association 
tests, an association between an intronic SNP in the PDE4D gene and sleepiness 
reached the genome-wide threshold of significance.  Usual bedtime was associated 
with the SNP rs324981, located in the gene NPSR1, which is a component of the 
neuropeptide S receptor.  More recently, a genome-wide association study of 
identified a genome-wide significant SNP in the ABCC9 gene as influencing sleep 
duration17, while a genome-wide scan of insomnia induced by caffeine failed to 
identify any genome-wide significant signals, but did replicate a previously reported 
association with a variant in the ADORA2A gene18. These investigations are important 
in establishing the feasibility of finding genetic associations with self-reported sleep 
phenotypes.  
 In order to advance our understanding of the genetics of sleep/wake regulation 
and insomnia there is a need for gene discovery studies that include a wider range of 
insomnia phenotypes and that have adequate sample sizes to detect what are likely to 
be small effects.  Here we present the results of a GWAS of sleep and circadian 
phenotypes in a sample of >2,000 Australian twins.  We tested >2,000,000 common 
genetic polymorphisms for association with sleep latency, sleep time, sleep quality, 
sleep depth, sleep duration and an insomnia factor score. We also tested the top hits 
from the sleep latency analysis for replication in an independent sample of 4 cohorts 
from the Chronogen Consortium. 
 
Methods 
Participants 
Between 1980 and 1982 a Health and Lifestyle Questionnaire was administered by 
mail to 5,867 complete pairs of twins who had been registered with the Australian 
Twin Registry. Responses were received from a total of 7,616 individuals (2,746 
males and 4,780 females) and they had a mean age of 34.5 years (S.D. = 14.3). 
Phenotypic and genotypic data collection was approved by the Queensland Institute of 
Medical Research (QIMR) Ethics Committee and informed consent was obtained 
from all participants. A total of 2,323 individuals provided both phenotypic and 
genotype information for the study (601 males and 1,721 females). The mean age for 
the genotyped sample was 31.4 years (S.D. = 11.0). A breakdown of the participants 
by zygosity is given in Table 1.   
 
Phenotypic Measures 
As part of the questionnaire, respondents were asked a number of questions about 
their sleep habits.  To assess usual sleep patterns participants were asked the 
following questions:  
 “On WEEKDAYS after you go to bed, what time do you usually try to get to 
sleep?”  (Self reported sleep onset time (SSOT)) 
“On WEEKDAYS, how long in minutes do you think it usually takes you to fall 
asleep from when you first try to go to sleep?”  (Sleep Latency) 
“How would you describe the quality of your usual sleep over the last few 
months?”  (Quality) 
1=Very good 2=Good  3=Fair  4=Poor 5=Very poor  
“In particular, how would you describe the depth of your sleep?“ (Depth) 
1=Hard to Wake 2=About average 3=Easy to wake 
“On WEEKDAYS, how long would you usually sleep for?”  (Sleep Duration) 
 
Participants were also asked about how much the quality of their sleep varies and 
about the frequency with which they wake up in the middle of the night. Further 
information on the sleep disturbance measures in the questionnaire can be found 
elsewhere 4,5,19. In total, six variables were analysed –  sleeptime, sleep latency, sleep 
quality, sleep depth, sleep duration and an insomnia factor score (I.F.S.). A factor 
analysis applied to an independent dataset that used a similar questionnaire also 
identified a factor that underscored poor sleep to which sleep latency, waking during 
the night, and sleep quality loaded strongly 20. Principal components analysis applied 
to this dataset previously showed that among the sleep measures assessed in the 
questionnaire - sleep quality, variability of quality, sleep latency and frequency of 
night-time waking - appear to load strongly on a general sleep disturbance component 
that measures general insomnia 4. In the present analysis, principal components 
analysis was performed on the same variables to derive an overall score for insomnia 
for each individual. The analysis supported a single factor loading on these variables. 
Descriptive statistics for each of the traits analysed are given in Table 2. An identical 
questionnaire (with regard to assessment of sleep habits) was administered to a 
subsample of 96 individuals who participated in a pilot study several months prior to 
the main study. This allowed us to test for consistency of responses over time. All of 
the individual sleep items analysed in this study showed good reliability (r2 >0.71, 
Table 2) 4. Previous analysis showed that the variables show strong internal 
consistency – a further indication of the validity of the subjective reports of sleep 
disturbance 4. The bivariate correlations between the variables are shown in 
Supplementary Table 1. There were significant age and sex effects, with sex being the 
most significant by several orders of magnitude. All of the analyses included age and 
sex as covariates. We also tested for effects of age2, age x sex, and age2 x sex, but 
there were no significant effects for any of these polynomial terms. Similarly, we 
tested for the effect of state of residency to check whether sleep patterns were affected 
by latitude, but no effects were detected.  Due to positive skew in the distribution of 
sleep latency and the insomnia factor score, both traits were natural log transformed 
(Table 2). In the case of the insomnia factor score, a constant was added to the scores 
to ensure that all scores were positive prior to transformation. For the SSOT analysis, 
individuals who said that they usually try to go to sleep between 3am and 6pm were 
removed from the analysis (n = 23), as there was a high likelihood that they were shift 
workers who were not choosing to sleep at that time by their own preference, or were 
individuals with delayed sleep phase syndrome. Individuals who reported regular use 
of sleeping tablets or tranquilisers (n = 15) were removed from the analysis.  
 As part of the protocol, participants were asked if they had ever had any of a 
number of conditions. Of potential relevance to sleep phenotypes were the following 
conditions: high blood pressure, heart attack, stroke, diabetes, thyroid trouble and 
cancer. A total of 258 individuals in the genotyped sample reported high blood 
pressure, 8 reported having diabetes, 95 reported thyroid trouble and 34 reported 
having had cancer. No participants who were included in this analysis reported having 
had a heart attack.  
Sleep duration has a very low estimated heritability in our data (9%) but was 
included in our analyses because it was a phenotype included in the only other 
genome-wide study reported to date 16. To reduce the effect of outliers on the 
analysis, individuals whose reported sleep duration was less than 5 hours or greater 
than 12 hours (n = 8) were removed from the analysis. The heritability of the I.F.S. 
was estimated to be 31%, in line with that found for insomnia phenotypes in other 
studies. This was also consistent with the estimates of the individual items, indicating 
there is no increase in heritability when combining information from many sleep 
phenotypes into a single insomnia phenotype.   
 
 
 
Genotyping 
Genotype information was collected as part of a number of genotyping projects 
undertaken by the Genetic Epidemiology group at Queensland Institute of Medical 
Research. DNA samples were collected in accordance with standard protocols and 
submitted to different genotype centres using different SNP platforms (Illumina 
317K, IlluminaHumanCNV370- Quadv3, and Illumina Human 610-Quad). 
Supplementary Figure 1 gives an overview of the number of individuals genotyped on 
each platform, including those genotyped in more than one genotyping project. SNPs 
were called using the Illumina BeadStudio software. A standard quality control 
procedure was used for all of the genotyping projects, prior to imputation. A detailed 
description of the quality control (QC) steps and procedure for detection of ancestry 
outliers is given elsewhere 21. A total of 22 individuals were removed from the present 
analysis due to being ancestry outliers.  
A set of 274,604 SNPs that were common to all of the genotyping chips were 
used for imputation, which was performed using the program MACH 22. The 
imputation process uses information on the haplotype structure in the human genome 
from the HapMap project (Release22 Build36) to impute non-genotyped SNPs in the 
sample. The imputed SNPs were screened further for Mendelian errors, minor allele 
frequency and missingness. Only SNPs with an imputation quality score (R2) greater 
than 0.3 were retained, which resulted in a total number of 2,380,486 SNPs. 
 
Genome-Wide Association Analysis 
Association analysis was performed using a score-test in MERLIN,23,24 with each 
SNP tested in a singlepoint analysis. This association test is appropriate for use with 
family data and allows inclusion of MZ and DZ pairs. The test combines information 
from both a within family test and a between family test to give an overall test of 
association. The analysis utilised the best-guess genotypes from the imputation 
analysis. A p-value < 5 x 10-8 was considered to be genome-wide significant.  
Post-GWAS analysis and annotation was carried out using the program WGAViewer 
25. Owing to the highly correlated nature of the results from imputed data because of 
linkage disequilibrium (LD) between the SNPs, some regions will have many SNPs 
with similar p-values. The clumping algorithm in PLINK 26 was used to filter results 
and find the most significant independent signals. SNPs with r2 < 0.5 were considered 
to be independent signals.  
 A large Finnish twin study that estimated the heritability of sleep quality 
found that the most parsimonious model was that the heritability was different for 
males and females27. We therefore analysed each trait in males and females separately 
in addition to the overall. It should be noted the power afforded by combining the 
results from the separate analyses in males and females affords less power than the 
overall analysis as the within family information from opposite sex twins is not 
incorporated into the by sex analyses. 
 
Power 
We used a simulation procedure in MERLIN to estimate the power afforded by our 
sample to detect variants that are associated with traits at the genome-wide 
significance level. The simulation procedure generates a dataset that has an identical 
distribution, heritability, marker informativeness, allele frequencies and missingness 
patterns and then permits testing for association with an allele that accounts for a 
specified portion of the phenotypic variance. For the present power analyses, we 
simulated a SNP with minor allele frequency of 0.25 that explains 1% of the variance 
for each of three traits – insomnia factor score, sleep latency and SSOT. These traits 
have estimated heritabilities of 31%, 32% and 42% in our sample. We performed 
1,000 replicates for each trait and the power was calculated as the proportion of those 
replicates for which the simulated variant was associated at a genome-wide 
significance level. We then used the Genetic Power Calculator to calculate the 
equivalent number of unrelated individuals that would be required to have the same 
power to detect association with the trait. 
 Supplementary Table 1 shows the statistical power of the study for variants 
explaining different proportions of the phenotypic variance. Our study has >80% 
power to detect a variant that explains 2% of the phenotypic variance at the genome-
wide significance level and approximately 99% power to detect a variant explaining 
3%.  Further, we estimate that our study had 19.4% power to detect a variant 
explaining 1% of the phenotypic variation in the insomnia factor score at a genome-
wide significant level. We had 16.2% power to detect the same variant in the sleep 
latency analysis and 19.5% power to detect it in the SSOT analysis. Approximately 
1,970 unrelated individuals would be needed to have the same power to detect the 
same variant. Approximately 4,280 unrelated individuals would be needed to have 
80% power to detect a variant explaining 1% of the phenotypic variance at a genome-
wide significant level (p < 5 x 10-8).  
 
Gene-Based Tests  
To determine whether there were any genes that harbour an excess of SNPs 
with small p-values, a gene-based test of association was performed 28. A SNP was 
considered to be part of a gene if it was located within 50kb of the start or stop site of 
the gene and so could be allocated to more than one gene. The test uses the p-values 
from the single SNP association analysis and computes an overall gene-based test 
statistic by aggregating the individual SNP effects in each gene, accounting for the 
number of SNPs in each gene, and the correlation between them because of LD.  The 
value of this test depends on the unknown true genetic architecture of causal variants 
which is likely to differ between genes. 
 
Pathway Analysis 
To test whether there was an enrichment of associations in genes that act in the same 
biological pathway or genes that have strongly related functions, all genes with a p-
value < 0.05 from the gene-based test were included in a pathway analysis in the 
Ingenuity Pathway analysis software (Ingenuity Systems Release 6.0, Ingenuity 
Systems, Redwood City, CA, USA).  The Ingenuity program collates information 
from published research articles regarding the structure, function, localisation and 
interactions of genes, proteins and biochemical molecules and assigns them to 
functional and canonical pathways. This permits testing for enrichment of a particular 
pathway that may be relevant to the trait of interest. Fisher’s Exact Test was used 
initially to test whether a particular pathway was overrepresented and the Benjamini-
Hochberg method was used to correct the p-values for multiple testing. A corrected p 
< 0.05 was considered to be significant. 
  
Candidate Loci and Genes 
We attempted to replicate the association findings of Gottlieb et al 16 for sleep 
duration and self-report sleep onset time. In addition, using the Ingenuity (Ingenuity 
Systems, Redwood City, CA, USA) software, we identified 86 genes that have been 
associated with sleep phenotypes in humans or animal models. We then checked 
whether SNPs within or near these genes showed evidence of association with the 
sleep phenotypes or if any of these genes ranked highly in the gene-based test of 
association.  
 
Replication Sample 
For replication of the top hit for sleep latency, the results of a meta-analysis of GWAS 
performed as a collaborative effort by the Chronogen Consortium were used. This 
comprised a total of 4,270 subjects with European ancestry and included samples 
from the Erasmus Rucphen Family (ERF), Estonian Genome Center (EGCUT), the 
Co-operative Health Research in the Augsburg Region (KORA), the KORCULA 
study in Croatia, the Micro-isolates in South Tyrol Study (MICROS), the Netherlands 
Study of Depression and Anxiety (NESDA) and the Orkney Complex Disease Study 
(ORCADES). However, only 4 of the studies provided information on SNPs in the 
LD block that was identified in the discovery analysis. A detailed description of these 
studies is provided in the supplementary methods. All studies in the replication cohort 
used the Munich Chronotype Questionnaire 29 to assess sleep traits. Sleep information 
only on free days, when a person’s sleep pattern was not influenced by professional 
duties (use of alarm clock was an exclusion criterion), was analyzed. Persons that 
used medications that may influence sleep were excluded from the analyses. Informed 
consents were obtained from all study participants and an appropriate local committee 
approved study protocols. Descriptive statistics for the replication cohorts are given in 
Table 3.  
 Replication cohorts were genotyped on a variety of platforms (Affymetrix 
250K, Illumina 317K, Illumina 370K; Perlegen 600K; Affymetrix 1000K). 
Imputations of non-genotyped SNPs in the HapMap CEU v21a or v22 were carried 
out within each study using MACH 22 or IMPUTE 30. Quality control was done in 
each group separately. The overall criteria were to exclude individuals with low call 
rate, excess heterozygosity, and gender mismatch. Based on sample size and study 
specific characteristics, different criteria were used. 
Individual GWAS was performed using linear regression (under additive 
model), natural log of sleep latency as the dependent variable, SNP allele dosage as 
predictor and age and sex as covariates. The association analyses were conducted in 
ProbABEL31 or SNPTEST 32. All cohorts with information on the top hit from the 
sleep latency discovery analysis used a linear mixed model in ProbABEL. The 
software incorporates the FASTA 24 method and kinship matrix estimated from the 
genotyped SNPs to correct for relatedness33 (the ERF and MICROS samples included 
related individuals). This method also accounts for cryptic population stratification. 
A fixed effects meta-analysis was conducted using the inverse variance 
weighted method as implemented in METAL34. Genomic control correction was also 
applied to all cohorts prior to the meta-analysis.  
  
 
Results 
The quantile-quantile (QQ) plots of the observed vs expected –log(p) from the six 
association analyses are presented in Supplementary Figure 2. There was no evidence 
for population stratification as demonstrated by the genomic control λ (the median χ2 
association statistic divided by the median expected under the null) being between 
0.99 and 1.02 for all of the analyses.  No SNPs passed the genome-wide significance 
threshold (p < 5 x 10-8) and there is no evidence for an enrichment of associations at 
the tail of the distribution. Manhattan plots for the analyses are given in 
Supplementary Figure 3. Table 4 lists the most significant SNPs that represent 
independent signals for each trait with p < 10-5 in the overall analysis and also their 
results separately by sex.   
A gene that has been previously associated with bipolar disorder CACNA1C 
(calcium channel, voltage-dependent, L type, alpha 1C subunit) on chromosome 12 
showed evidence for association with sleep latency and with sleep quality. A set of 
SNPs in perfect LD located in the 3rd intron (rs7316184, rs7304986, rs7301906, 
rs16929275, rs16929276, rs16929278, rs2051990) each with minor allele frequency 
~0.014 were the most strongly associated SNPs with sleep latency (Table 4, p = 1.3 x 
10-6). The SNPs were genome-wide significant when the analysis was performed on 
the untransformed residuals (p = 4.9 x 10-10), but this did not remain after 
transforming the distribution to log-normal. These SNPs were not in LD with the 
validated bipolar variants 35 subsequently found to be associated with schizophrenia 
and recurrent major depression 36 (rs1006737 and rs10848635 also in intron 3, r2 with 
rs7316184 etc  = 0.018 and 0.006) and so represent an independent signal. We 
attempted to replicate the association with the CACNA1C SNPs in an independent 
sample comprising 7 cohorts with a total sample size of 4,260 that had collected 
information on sleep latency. Of these, 4 cohorts had the rs7304986 variant genotyped 
or imputed (sample size = 2,001). Three of the cohorts had the same direction of 
effect as found in the initial GWAS, with the minor allele found to increase sleep 
latency. The association was not nominally significant however (p = 0.73) (Table 5). 
We also performed a meta-analysis of the Australian results and the results from the 4 
cohorts in Chronogen in which results for rs7304986 were available (Table 5). The p-
value for the meta-analysis was 0.01 (β = 0.12, S.E. = 0.05). 
For the SSOT analysis, there were two SNPs located in or near genes with p < 
10-5. They are intronic SNPs in the L3MBTL4 and EBF3 genes respectively (Table 4). 
L3MBTL4 is a gene on chromosome 18 whose function is not well annotated. EBF3 is 
located on chromosome 10 and is known to be expressed in the brain. It is frequently 
found to be silenced in brain tumours and other forms of cancer and is thought to be a 
tumour suppressor gene 37. No circadian candidate genes harbor SNPs that show 
strong evidence of association with timing of sleep from our analysis. One SNP – 
rs10734107 – located 2kb downstream of the NPS gene had a p-value of 1.1 x 10-5. 
NPS is an interesting candidate gene for association with sleep timing as it encodes a 
Neuropeptide S, a molecule that is known to stimulate arousal and that has been 
associated with anxiety and sleep apnea 38. In a previous GWAS of SSOT16, a SNP in 
the Neuropeptide S Receptor gene (rs324981) was among the most associated variants 
(p = 4.5 x 10-5). That result did not replicate in our study (p = 0.133), but the 
combined findings of the two genome-wide studies implicate a role for the 
Neuropeptide S system in sleep/wake regulation. 
 The CACNA1C gene also shows evidence of association with sleep quality 
(Table 4). The most significant SNP from this region - rs2302729 (p = 4.4 x 10-6) – is 
located in intron 9 of the gene and is not in LD with the variants associated with sleep 
latency (r2 = 0.004) or with the SNPs associated with bipolar disorder (r2 = 0.009 and 
0.034 respectively).  
 For the sleep depth analysis, there were only two independent regions 
associated with p < 10-5, neither of which were located within or near annotated 
genes. The most significantly associated SNP with sleep duration was rs4780805 (p = 
2.66 x 10-6). This SNP is located on chromosome 16, 17kb from the nearest gene 
TMC5.  
A SNP – rs11174478 (p = 1.92 x 10-6) in the SLC2A13 gene is the most 
strongly associated with the insomnia factor score. This gene is located in the same 
region of the genome as LRRK2, a gene known to be associated with Parkinson’s 
Disease. 
No SNPs reached genome-wide significance when males and females were 
analysed separately. The results from those analyses are available upon request. 
 
Gene-based Tests and Pathway Analysis 
At least one SNP mapped to 17,695 autosomal genes. A conservative genome-wide 
threshold for significance was set at 2.83 x 10-6, which corresponds to a nominally 
significant p-value of 0.05 corrected for 17,695 tests. This threshold does not correct 
for analysing multiple (albeit correlated) traits. No genes reached this significance 
threshold. A list of the five most significant genes for each trait is given in Table 6. 
The most significant association across the six traits was ZNF695 with sleep duration 
(p = 1.14 x 10-4). None of the most strongly associated genes on the list have a known 
role in circadian rhythms or have previously been identified as candidate genes for 
sleep phenotypes. 
 After correction for multiple testing, no biological functions or pathways were 
found to be enriched in the gene-based test. Supplementary Table 3 gives the most 
significant functions and pathways for each of the gene-based analyses.  
 
Candidate Genes 
From the Ingenuity Pathway Analysis software, we identified 86 genes that have been 
associated with circadian rhythms and sleep phenotypes in humans or animal models. 
In addition, we examined the association statistics for a further 9 genes identified in 
the study of Gottlieb et al 16. The most strongly associated SNP and results from the 
gene-based test for each of the candidate genes are given in the Supplementary File. 
With the exception of NPS in the sleep latency analysis, none of the candidate genes 
ranked among the most associated genes for any of the traits. Strikingly, the NPS 
ranked top of the candidate genes for SSOT (p = 0.001) and fourth in the latency 
analysis (p =0.03), indicating that variants within the gene may influence several 
different sleep phenotypes. This result is not unsurprising given that the principal 
components analysis showed that the variables load on one common factor for 
insomnia. The number of genes with p < 0.05 ranged from 0 for sleep duration to 7 
for sleep latency and there was no overall evidence for an enrichment of associations 
in the candidate genes. A list of SNPs located either in the gene or within 50kb of the 
start of stop site with p < 10-3 for any of the association analyses are listed in 
Supplementary Table 4.  
  Gottlieb et al identified 34 SNPs that showed evidence of association - in 
either a population-based or family-based test – or linkage with sleep duration, SSOT 
or sleepiness. We attempted to replicate those SNPs in our sample initially with the 
phenotypes for which associations had been reported, and then with the other 
phenotypes in our study. No measure of sleepiness was available in this study and so 
it was not possible to try to replicate the top SNPs for that phenotype. Only one SNP 
replicated with the same phenotype – rs2985334 with SSOT (p = 0.0062 β = 5.3 
minutes), survived multiple testing. Several of the other SNPs replicated with other 
phenotypes in the sample, but none of these results were significant after accounting 
for multiple testing. A list of SNPs from Gottlieb et al with p < 0.05 for association 
with any of the phenotypes is given in Supplementary Table 4.  
 
Discussion 
A GWAS of six insomnia-related traits in a sample of over 2,000 Australian twins and 
their siblings (with power equivalent to 1,970 unrelated individuals) was performed. 
One previous GWAS of sleep and circadian phenotypes has been reported, but the 
analysis was limited to ~71,000 SNPs with minor allele frequency > 0.1. The present 
study used > 2,000,000 SNPs in the analysis and so surveys a larger fraction of the 
common variation in the human genome and has a larger sample size. No SNPs 
reached the genome-wide significance level for any of the traits. The Q-Q plots show 
that the distribution of the association test statistics closely follows the expected 
distribution under the null hypothesis of no association. This is not an unexpected 
finding given the sample size of the study and the effect sizes of variants detected in 
genome-wide association studies of other complex trait 39-41. This contrasts with the 
Q-Q plot for a similar study of hair morphology that used the same sample used in the 
present analysis and found a genome-wide significant hit 21.  
The top ranked region for the sleep latency analysis was the 3rd intron of the 
CACNA1C gene. Variants in this intron have previously been found to be associated 
with a number of psychiatric disorders including bipolar disorder and 
schizophrenia.35,36 While the SNPs identified here are not in LD with the risk alleles 
and therefore represent an independent signal, there is widespread evidence to suggest 
a link between sleep disturbance and mood disorders and several studies have 
reported associations between circadian genes and mood disorders42-44. It is therefore 
plausible that variants in genes known to increase risk to mood disorders may also 
play a role in sleep disturbance. The association did not replicate in an independent 
sample however (p = 0.71, meta-p = 0.01), indicating that it may simply be a chance 
occurrence that these SNPs are associated in our sample.  
The lack of replication may be caused by several factors. The replication 
sample size was 2,001 individuals, which includes some related samples. Under the 
assumption that the true causal variant at the CACNA1C locus has been detected and 
the effect size has been estimated without error, the estimated proportion of variance 
in sleep latency explained is 0.5%. From the Genetic Power Calculator it can be 
calculated that the replication sample had 89.12% power to detect the same effect 
with p < 0.05. However, because of the “winner’s curse effect”, the true effect size 
may have been overestimated in the discovery sample and hence the power to 
replicate the finding may in fact be less than estimated. In addition, there were some 
differences between the discovery and replication samples that could have affected 
the results. Firstly, the questionnaires used to collect latency information were 
different, with the discovery sample asking about sleep latency on weekdays while the 
replication sample asked about free days which may have led to slight differences in 
the phenotypes. Secondly, differences in inclusion criteria between the discovery and 
replication cohorts and between the individual replication cohorts may have decrease 
the power to replicate the finding. The NESDA sample removed individuals from the 
analysis who had major depressive disorder, whereas the Australian questionnaire did 
not include a diagnostic interview for mood disorders and so could not remove 
individuals with depression from the analysis. Moreover, the mean age of the 
discovery cohort (31.28 years) was younger than all of the replication cohorts 
(Supplementary Table 2), which may have affected the power to replicate. This 
heterogeneity between cohorts is likely to be an issue in many genetic association 
studies of sleep and insomnia (not just those that rely on self-report information) and 
so very large sample sizes may be required to have enough power to have enough 
power to find variants of small effect. 
In spite of the lack of replication, CACNA1C represents an interesting 
candidate gene for sleep phenotypes, not only because of its known association with 
bipolar disorder. An association study of narcolepsy in a Japanese population 
implicated another SNP in the 3rd intron of CACNA1C (rs10774044, p = 4.2 x 10-4) 45. 
The SNP identified in the narcolepsy study is not in LD in the European population 
with the SNPs identified in the present study (r2 = 0.001), but it is nominally 
associated with sleep latency in our sample (p = 0.035, β = 0.054, M.A.F = 0.048). An 
independent region of CACNA1C was also suggestively associated with sleep quality 
in our sample and it is known that hypocretin 1, a neuropeptide that promotes 
wakefulness, activates the L-type voltage-dependent calcium channels among other 
signalling pathways in the brain 46. There is therefore evidence from a number of 
sources implicating CACNA1C in sleep/wake regulation, and despite the lack of 
replication for the SNPs identified here, further studies of the role of this gene in 
regulating sleep are warranted.  
 Studies in rats have shown that increased concentrations of neuropeptide S can 
activate the hypocretin-1 system, and this may explain the effect of neuropeptide S on 
arousal. NPS is a strong candidate gene for circadian phenotypes due to its established 
effects on wakefulness. Mice exposed to even small amounts of NPS show increased 
locomotion and NPS has been shown to decrease paradoxical and slow wave sleep in 
rats 38. While the result did not replicate in our study, the finding of a significant SNP 
located in the gene encoding the receptor for NPS in a previous study also strongly 
implicates the biological pathway in which NPS acts in controlling timing of sleep in 
humans.  
 The single SNP analysis and the gene-based test both implicate a region on 
chromosome 12 near the SLC2A13 and LRRK2 genes as the most strongly associated 
with the insomnia factor score. This region has previously been identified as being 
associated in Parkinson’s disease 47. One of the most common features of Parkinson’s 
is sleep disruption however none of the genome-wide significant SNPs from the 
Parkinson’s GWAS were nominally significant in our sample. 
Our study had several limitations that need to be borne in mind when 
interpreting the results and that may have affected the power of our study. We 
estimated the power to detect a variant that explains 2% of the phenotypic variance in 
any of the traits as ~80%, while the power to detect a variant explaining 1% of the 
variance was ~18%. However, this may be an overestimate for several reasons. 
Firstly, we were unable to systematically examine whether participants 
undertook shift work. We did remove those individuals who said that their usual 
bedtime was after 2am, and who may therefore have worked unusual hours that could 
have contributed to sleep difficulties. However, there may have been others in the 
sample that did usually go to sleep in the evening, but who had to do shift work that 
caused significant circadian disruption.  
Secondly, as mentioned above, we were also unable to establish whether any 
of the participants were suffering from a psychiatric disorder, as questions relating to 
symptoms were not included. While we did ask about conditions that may have 
affected sleep such as serious heart disease and stroke, we did not ask about a range of 
other conditions that may have affected responses to the sleep questionnaire.   
Thirdly, even in the absence of any comorbidities, self-report sleep 
phenotypes are subject to cognitive and perceptual biases that may reduce power to 
detect associations with genetic variants. Individuals who experience sleep 
disturbance may be prone to underestimate their usual sleep duration. The gold 
standard for the assessment of sleep is polysomnography, with actigraphy offering 
another objective measure that also can be used to measure activity rhythms in 
humans. These methods provide more objective measures of sleep and circadian 
phenotypes which may be more amenable to genetic analysis. As an example, certain 
polysomnographic components have been shown to be > 90% heritable 48. The 
disadvantage of these methods is that they are expensive and time-consuming and so 
large genetically informative samples measured for these phenotypes will be difficult 
to obtain. Studies comparing self-reported sleep information to objective measures 
have shown a strong correlation between them and those reporting poorer sleep tend 
to have increased time to fall asleep, less total sleep duration and increased night 
waking. The self-report items used in the present study showed good test-retest 
correlations indicating their stability over time and the items were internally 
consistent which provides another check of the validity of the self-report items. 
Moreover, the measures used in this study have been validated against laboratory-
based EEG measures of sleep 49. However, EEG-based measures of sleep remain the 
most desirable phenotypes for genetic analysis. 
 In this study, we focussed primarily on analysing both sexes together in order 
to maximise statistical power. Some studies have identified sex-specific genetic 
effects, including an increased heritability of sleep quality in females 27. For the 
majority of the associations identified in the overall analysis, there was a nominally 
significant association in both sexes. Males comprised a smaller percentage of the 
sample and therefore there was less power to detect associations when analysing 
males alone. However, several of the associations showed more evidence of 
association in one sex when compared to the other. Future replication efforts might be 
successful by trying to replicate the results in males or females only. 
 Confirmation of the association in an independent sample is required before an 
association can be considered “real” rather than simply a chance event. All our 
associations are at a level expected under the null hypothesis given the extent of 
multiple testing. However, this study has identified a number of suggestive 
associations that can be prioritised for replication in other samples. We attempted to 
replicate the top SNP for sleep latency in an independent consortium of cohorts. 
However, attempted replication in an even larger sample would be desirable, while 
the top hits for the other 5 traits will also be necessary.  
 The somewhat mixed results from candidate gene studies for sleep/wake 
regulation also highlight the need for replication in association studies. This study 
also permitted us to attempt replication of candidate genes and polymorphisms 
identified in candidate gene association studies for sleep, but none of them were 
replicated in our study.  
 In spite of the limitations of the study, we have identified a number of 
common variants that are suggestively associated with variation in sleep habits in the 
population, some of which are located in or near candidate genes. These variants 
should be targeted for replication in other samples. It is likely that larger sample sizes 
(likely on the order of tens of thousands of individuals) will be required to identify 
common variants that influence self-report sleep habits in the population. However, 
any identified variants, genes or biological pathways may have a dramatic impact on 
our understanding of sleep/wake regulation and will have implications for general 
medicine, given the link between disturbed sleep and cardiovascular disease 50, 
psychiatric illness 51, life satisfaction and wellbeing 27. Our results will be useful for 
replication efforts in independent samples and for future meta-analyses. 
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 ERF: The Erasmus Rucphen Family study is a family based study that includes over 
3000 participants descending from 22 couples living in the Rucphen region in the 19th 
century. All living descendants of these couples and their spouses were invited to take 
part in the study. 1700 individuals from this population were assessed for sleep 
latency. After strict quality control  and removing individuals on medications that 
could affect sleep patterns 940 were available for the analysis, of which 740 
individuals (58% females) were used in the genome-wide analysis.(Aulchenko and 
others 2004)  
EGCUT: The Estonian Genome Center, University of Tartu (EGCUT) is a bio-bank 
consisting of data of 40000 individuals from a population based Estonian cohort aged 
18 years and older (67% females).(Metspalu 2004) For the current study, GWAS was 
performed on 933 subjects with both Illumina HumanCNV370 genotype (array 
according to Illumina protocol in Estonian Biocenter Genotyping Core Facility) and 
MCTQ questionnaire data available. The age range was 18-86 years (mean 39.8 (SD 
16.1) years). The current sample consists of 412 males (mean age 38.4 (SD=16.2) 
years) and 521 females (mean age 41.0 (SD=15.9) years). 
Cooperative Health Research in the Augsburg Region (KORA): The KORA F4 study 
is a follow-up study to the KORA-Survey 2000 (S4, 10/1999 – 7/2001). It was 
conducted between October 2006 and May 2008. It was conducted between October 
2006 and May 2008. From KORA F4 survey (full cohort n = 3080), 1814 individuals 
between 32 to 81 years were selected for Genotyping on Affymetrix 
1000K.(Wichmann and others 2005) The current study includes 548 individuals that 
provided both sleep information and genotypes and who passed quality control. 
MICROS: The Micro-isolates in South Tyrol Study (MICROS) study is part of the 
genomic health care program 'GenNova' and was carried out in three villages of the 
Val Venosta on the populations of Stelvio, Vallelunga and Martello. This study was 
an extensive survey carried out in South Tyrol (Italy) in the period 2001-2003. An 
extensive description of the study is available elsewhere.(Pattaro and others 2007) 
Briefly, study participants were volunteers from three isolated villages located in the 
Italian Alps, in a German-speaking region bordering with Austria and Switzerland. 
Information on the health status of participants was collected through a standardized 
questionnaire. Laboratory data were obtained from standard blood analyses. 
Genotyping was performed on just under 1,400 participants with 1,334 available for 
analysis after data cleaning. 
NESDA: The Netherlands Study of Depression and Anxiety includes 1763 unrelated 
cases with a current or remitted major depressive disorder and healthy controls. For 
the present study 540 subjects without a current major depressive disorder who passed 
phenotype and quality control were used for the analysis. The average age of the 
included participants was 41.3 years (66% females).(Boomsma and others 2008)  
ORCADES: The Orkney Complex Disease Study is a family-based cross sectional 
genetic epidemiological study in the isolated Scottish islands of Orkney. Genetic 
diversity is decreased compared to the mainland Scottish samples, consistent with 
high extent of endogamy. The current study included 424 individuals (37% females) 
that had both directly observed and imputed genotypes and were also assessed for 
sleep patterns with MCTQ questionnaire. 
 
Table 2. Descriptive statistics for each of the phenotypes and test-retest correlations 
* Higher scores for the Quality and Depth variables indicate poorer quality and lighter depth of sleep   
 
No of 
individuals 
Heritability 
(h2) Minimum Maximum Mean Std. Dev 
Reliability 
Latency 
raw 
scores 
(minutes) 
2280 0.32 1 180 20.98 22.94 
0.72 
Latency 
(natural 
log) 
2280 0.32 -1.21 5.48 2.67 0.9 
- 
Quality 2315 0.32 1.00 5.00 1.99 0.87 
0.78 
Depth 2314 0.21 1.00 3.00 1.78 0.65 
0.82 
Sleeptime 2322 0.42 8:00PM 2:30AM 10:42PM 52.75 minutes 
0.81 
Sleep 
Duration 
2278 0.09 5 hours 12 hours 7.73 
hours 
0.91 hours 
0.74 
I.F.S. 
(natural 
log) 
2267 0.31 -1.91 
 
1.72 0.11 0.67 
 
- 
 Table 4. Descriptive statistics for cohorts in Chronogen Consortium 
 
Population sample Average sleep 
latency (sd) 
Average [LN(sleep 
latency + c)](sd) 
Average age 
(sd) 
 
 
 
EGP Total 15.47(17.76) 2.31(1.02) 39.85(16.08) 
Male 14.38(15.74) 2.25(1.01) 38.38(16.24) 
Female 16.54(19.70) 2.37(1.04) 41.03(15.88) 
ERF Total 17.69(18.63) 2.56(0.85) 45.67(13.00) 
Male 15.53(14.99) 2.48(0.80) 47.42(12.98) 
Female 19.59(21.16) 2.64(0.88) 44.12(12.83) 
KORA Total 10.33 (9.72) 2.08(0.79) 54.29 (5.49) 
Male 8.71 (7.75) 1.95 (0.77) 54.64(5.66) 
Female 11.97 (11.16) 2.21 (0.81) 53.96 (5.32) 
KORCULA Total 19.55(12.15) 2.56(1.02) 56.41(12.2) 
Male 17.58(13.86) 2.52(0.94) 57.61(12.97) 
Female 20.69(18.71) 2.59(1.07) 55.72(11.7) 
MICROS Total 13.31(14.29) 2.22(0.94) 40.26(14.52) 
Male 11.94(12.06) 2.16(0.89) 41.24(14.50) 
Female 14.50(15.88) 2.28(0.98) 39.44(14.53) 
NESDA Total 18.52 (18.52) 2.60 (0.90) 41.25 (12.26) 
Male 16.63 (16.95) 2.52 (0.85) 44.15 (12.40) 
Female 19.49 (19.22) 2.64 (0.93) 39.77 (11.94) 
ORCADES 
 
 
Total 15.95(15.61) 2.36(1.00) 51.08(11.08) 
Male 12.67(11.26) 2.22(0.89) 51.08(13.18) 
Female 18.67(18.2) 2.47(1.08) 51.26(13.85) 
QIMR Total 20.98 (22.94) 2.67(0.90) 31.28 (10.88) 
Male 17.67 (16.26) 2.56 (0.86) 28.17 (8.12) 
Female 22.14 (24.78) 2.71 (0.92) 32.37 (11.51) 
Table 1 Breakdown of the sample by zygosity 
MZ female pairs 492 
MZ male pairs 102 
DZ female pairs 122 
DZ male pairs 59 
Opposite Sex DZ pairs 125 
Female  siblings of twins 33 
Male siblings of twins 5 
Female non-twin singletons 335 
Male non-twin singletons 150 
Total Sample Size 2,323  
Table 6. The 5 most significant genes from the gene-based test for each of the traits analysed    
 
Gene Trait Chr P-value nSNPs Start Stop Best-SNP SNP-pvalue 
RSPRY1 Duration 16 1.30E-05 69 55777741 55830448 rs11640439 1.50E-06 
NIP30 Duration 16 2.00E-05 84 55743878 55777477 rs767505 5.77E-05 
CPNE2 Duration 16 4.40E-05 127 55684010 55739377 rs767505 5.77E-05 
ARL2BP Duration 16 9.20E-05 36 55836538 55845046 rs11640439 1.50E-06 
GPR68 Duration 14 1.74E-04 76 90768628 90789977 rs2540871 1.93E-06 
SIP1 Latency 14 3.12E-04 82 38653238 38675928 rs8011494 6.23E-05 
LOC284009 Latency 17 3.48E-04 61 2257024 2265480 rs898751 8.86E-04 
TRAPPC6B Latency 14 4.97E-04 73 38686765 38709385 rs8011494 6.23E-05 
SEC23A Latency 14 5.23E-04 121 38570873 38642188 rs8011494 6.23E-05 
C13orf39 Latency 13 6.06E-04 151 102136097 102144855 rs679331 3.75E-04 
NGRN Sleeptime 15 4.53E-04 87 88609898 88616447 rs1044813 5.29E-05 
TTLL13 Sleeptime 15 6.41E-04 84 88593767 88603316 rs1044813 5.29E-05 
FLT3 Sleeptime 13 6.83E-04 136 27475410 27572729 rs9554235 2.01E-04 
CIB1 Sleeptime 15 6.84E-04 80 88574480 88578283 rs1044813 5.29E-05 
C15orf58 Sleeptime 15 7.66E-04 82 88578490 88586316 rs1044813 5.29E-05 
ZNF695 Quality 1 1.14E-04 82 245215248 245237978 rs10802457 8.56E-05 
SLC2A13 Quality 12 1.22E-04 568 38435089 38785928 rs1005956 2.61E-06 
TM4SF20 Quality 2 3.52E-04 107 227935117 227952266 rs11693555 1.28E-03 
SLC39A2 Quality 14 4.30E-04 111 20537258 20539870 rs1889774 6.71E-05 
METT11D1 Quality 14 4.39E-04 105 20527804 20535034 rs1889774 6.71E-05 
CLNS1A Depth 11 1.29E-04 50 77004846 77026495 rs17135809 9.74E-05 
RSF1 Depth 11 1.32E-04 115 77054921 77209528 rs1544274 9.74E-05 
PNMA2 Depth 8 1.71E-04 174 26418112 26427400 rs1372882 3.14E-05 
LRRN2 Depth 1 4.26E-04 142 202852925 202921220 rs2772232 1.50E-04 
LYPLA3 Depth 16 5.12E-04 38 66836747 66852462 rs6499163 7.15E-04 
LRRK2 I.F.S 12 3.64E-04 583 38905079 39049353 rs11564146 1.33E-04 
IER5L I.F.S 9 5.07E-04 122 130977651 130980361 rs1107329 5.71E-04 
CSDA I.F.S 12 5.89E-04 114 10742954 10767171 rs797168 1.43E-04 
CRAT I.F.S 9 6.18E-04 110 130896893 130912904 rs12346996 4.66E-04 
DOLPP1 I.F.S 9 6.53E-04 82 130883226 130892538 rs12346996 4.66E-04 
